India, Nov. 19 -- Halozyme Therapeutics, Inc. (HALO) said a German appeals court has overturned a preliminary injunction that had previously ordered Merck (MRK) to stop distributing and offering Keytruda SC in Germany.
The dispute centers on Halozyme's MDASE patent portfolio, which relates to technologies used in subcutaneous, or under the-skin, drug administration. Halozyme alleges that Merck's subcutaneous formulation of Keytruda infringes certain patents.
Halozyme Plans New Legal Action
Following the court's decision, Halozyme said it will immediately file a patent infringement lawsuit in Germany seeking a permanent ruling against Merck.
The company stated that the latest decision applies only to the preliminary injunction and does n...